Drug
Raavrh74 Mhck7 Dysf DV
Raavrh74 Mhck7 Dysf DV: highest development phase Phase 1, developed by Sarepta Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| rAAVrh74.MHCK7.DYSF.DV NCT02710500 | Phase 1 | Dysferlinopathy |
Latest
No recent events.
Follow Raavrh74 Mhck7 Dysf DV on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.